Oxytocin and Vasopressin Agonists and Antagonists as Research Tools and Potential Therapeutics

Journal of Neuroendocrinology

Volumn 24, Issue 4, 2012, Pages 609-628

  Manning, M ^a   Misicka, A ^a,b   Olma, A ^a,c   Bankowski, K ^a,d   Stoev, S ^a   Chini, B ^e   Durroux, T ^f   Mouillac, B ^f   Corbani, M ^f   Guillon, G ^f  

^a MEDICAL COLLEGE OF OHIO   (United States)

^b UNIVERSITY OF WARSAW   (Poland)

^c LODZ UNIVERSITY OF TECHNOLOGY   (Poland)

^d INDUSTRIAL CHEMISTRY RESEARCH INSTITUTE   (Poland)

^e CNR   (Italy)

^f INSTITUT DE GÉNOMIQUE FONCTIONNELLE   (France)

Author keywords

Agonists; Antagonists; Non peptide; Oxytocin; Peptide; Vasopressin

Indexed keywords

1 [1 [4 (1 ACETYL 4 PIPERIDINYLOXY) 2 METHOXYBENZOYL] 4 PIPERIDINYL]BENZ[D][1,3]OXAZIN 2 ONE; 1 [1 [4 (3 ACETAMIDOPROPOXY)BENZOYL] 4 PIPERIDYL] 1,2,3,4 TETRAHYDRO 2 QUINOLINONE; 1 [[[2 [2 AMINO 4 (METHYLSULFONYL)BUTYRAMIDO] 7,7 DIMETHYLBICYCLO[2.2.1]HEPTAN 1 YL]METHYL]SULFONYL] 4 (2 METHYLPHENYL)PIPERAZINE; ARGIPRESSIN RECEPTOR; ATOSIBAN; CARBETOCIN; CONIVAPTAN; DESMOPRESSIN; FE 202158; FE 202767; L 368 899; L 371 257; LYPRESSIN; MOZAVAPTAN; NELIVAPTAN; ORNIPRESSIN; OXYTOCIN ANTAGONIST; OXYTOCIN RECEPTOR; PF 00738245; RELCOVAPTAN; RETOSIBAN; SATAVAPTAN; TERLIPRESSIN; TOLVAPTAN; UNCLASSIFIED DRUG; VASOPRESSIN ANTAGONIST; VASOPRESSIN V1A RECEPTOR; VASOPRESSIN V1B RECEPTOR; VASOPRESSIN V2 RECEPTOR; WAY 162720; WAY 267464;

AMINO ACID SUBSTITUTION; ANTIDIURESIS; BIOASSAY; BIOLUMINESCENCE RESONANCE ENERGY TRANSFER; DIABETES INSIPIDUS; DIMERIZATION; DRUG APPROVAL; DRUG DESIGN; DRUG DISCRIMINATION; DRUG INDUSTRY; DRUG MECHANISM; DRUG RECEPTOR BINDING; DRUG RESEARCH; DRUG SELECTIVITY; DRUG SYNTHESIS; FLUORESCENCE RESONANCE ENERGY TRANSFER; HUMAN; HYPONATREMIA; HYPOTENSION; IN VITRO STUDY; IN VIVO STUDY; ISOTOPE LABELING; NONHUMAN; PEPTIDE SYNTHESIS; PREMATURE LABOR; PRIORITY JOURNAL; REVIEW; SPECIES DIFFERENCE; VASODILATING HYPOTENSION;

ANIMALS; ARGININE VASOPRESSIN; CLINICAL TRIALS AS TOPIC; DRUG EVALUATION, PRECLINICAL; HUMANS; OXYTOCIN; RECEPTORS, OXYTOCIN; RECEPTORS, VASOPRESSIN; STRUCTURE-ACTIVITY RELATIONSHIP;

EID: 84858808581     PISSN: 09538194     EISSN: 13652826     Source Type: Journal    
DOI: 10.1111/j.1365-2826.2012.02303.x     Document Type: Review

References (246)

1. 2 and OT Receptors: Research Tools and Potential Therapeutic Agents. In: Landgraf R, Neumann I, eds. Prog Brain Res Amsterdam: Elsevier, 2008: 473-512.
2. du Vigneaud V, Ressler C, Swan JM, Roberts CW, Katsoyannis PG. The synthesis of oxytocin. J Am Chem Soc 1954; 76: 3115-3121.
3. du Vigneaud V, Gish DT, Katsoyannis PG. A synthetic preparation possessing biological properties associated with arginine-vasopressin. J Am Chem Soc 1954; 76: 4751-4752.
4. Merrifield RB. Solid phase peptide synthesis. I. The synthesis of a tetrapeptide. J Am Chem Soc 1963; 85: 2149-2154.
5. Manning M. Impact of the Merrifield solid phase method on the design and synthesis of selective agonists and antagonists of oxytocin and vasopressin: a historical perspective. Biopolymers 2008; 90: 203-212.
6. Sawyer WH, Manning M. Synthetic analogues of oxytocin and vasopressin. Annual Rev Pharmacol 1973; 13: 5-17.
7. Manning M, Grzonka Z, Sawyer WH. Synthesis of posterior pituitary hormones and hormone analogues. In: Beardwell C, Robertson G, eds. The Pituitary. Kent: Butterworth, 1981: 265-296.
8. Sawyer WH, Grzonka Z, Manning M. Neurohypophyseal peptides: design of tissue-specific agonists and antagonists. Mol Cell Endocrinol 1981; 22: 117-134.
9. Manning M, Sawyer WH. Development of Selective Agonists and Antagonists of Vasopressin and Oxytocin. In: Schrier R, ed. Vasopressin. New York, NY: Raven Press, 1985: 131-144.
10. Manning M, Bankowski K, Sawyer WH. Selective agonists and antagonists of vasopressin. In: Gash DM, Boer GJ, eds. Vasopressin: Principles and Properties. New York, NY: Plenum Press, 1987: 335-368.
11. Manning M, Sawyer WH. Discovery, development, and some uses of vasopressin and oxytocin antagonists. J Lab Clin Med 1989; 114: 617-632 [Published erratum appears in J Lab Clin Med 1990; 115: 530].
12. Barberis C, Morin D, Durroux T, Mouillac B, Guillon G, Hibert M, Tribollet E, Manning M. Molecular pharmacology of vasopressin and oxytocin receptors and therapeutic potential. Manning. Drug News Perspect 1999; 12: 279-292.
13. Manning M, Sawyer WH. Design, synthesis and some uses of receptor specific agonists and antagonists of vasopressin and oxytocin. J Receptor Res 1993; 13: 195-214.
14. Manning M, Sawyer WH. Antagonists of vasopressin and oxytocin: current status and future perspectives. In: Jard S, Jamison R, eds. Vasopressin. London: Coll Inserm/John Libbey Eurotext, 1991: 297-309.
15. Chan WY, Wo NC, Stoev S, Cheng LL, Manning M. Discovery and design of novel and selective vasopressin and oxytocin agonists and antagonists: the role of bioassays. Exp Physiol 2000; 85(Suppl.): 7S-18S.
16. Manning M. Neurohypophyseal peptide agonists and antagonists: a five decade trail from du Vigneaud to 2004. In: Flegel M, Fritkin M, Gilon C, Slaninova S, eds. Peptides 2004. Geneva: Kenes International, 2005: 101-106.
17. Berde B, Boissonnas RA. Basic pharmacological properties of synthetic analogues and homologues of the neurohypophysial hormones. In: Berde B, ed. Neurohypophysial Hormones and Similar Polypeptides, Handbook of Experimental Pharmacology 23. Berlin: Springer Verlag, 1968: 802-870.
18. Lebl M. Analogs with inhibitory properties. In: Jost K, Lebl M, Brtnik F, eds. Handbook of Neurohypophyseal Hormone Analogs, Vol. 2, Part 1, Part 2. Boca Raton, FL: CRC Press, 1988: 17-72, 127-267.
19. 1a receptors as new therapeutic targets in assisted reproduction. Reprod Biomed Online 2011; 22: 9-16.
20. Hruby VJ, Smith CW. Structure-activity relationships of neurohypophyseal peptides. In: Udenfriend S, Meienhofer J, eds. The Peptides: Analysis, Synthesis, Biology, Vol. 8. In: Chemistry, Biology, and Medicine of Neurohypophyseal Hormones and Their Analogs, vol. ed. Smith CW, New York, NY: Academic Press, 1987: 77-207.
21. Frank E, Landgraf R. The vasopressin system - from antidiuresis to psychopathology. Eur J Pharmacol 2008; 583: 226-242.
22. Jard S. Vasopressin receptors. A historical survey. In: Zingg HH, Bourque CW, Bichet DG, eds. Adv Exp Med Biol New York, NY: Plenum Press, 1998: 1-13.
23. Gimpl G, Fahrenholz F. The oxytocin receptor system: structure function and regulation. Physiol Rev 2001; 81: 629-683.
24. Insel TR, Young LJ. The neurobiology of attachment. Nat Rev Neurosci 2001; 2: 129-136.
25. Bosch OJ, Meddle SL, Beiderbeck DI, Douglas AJ, Neumann ID. Brain oxytocin correlates with maternal aggression: link to anxiety. J Neurosci 2005; 25: 6807-6815.
26. Huber D, Veinante P, Stoop R. Vasopressin and oxytocin excite distinct neuronal populations in the central amygdala. Science 2005; 308: 245-248.
27. Ma S, Shipston MJ, Morilak D, Russell JA. Reduced hypothalamic vasopressin secretion underlies attenuated adrenocorticotropin stress responses in pregnant rats. Endocrinology 2005; 146: 1626-1637.
28. Parker KJ, Buckmaster CL, Schatzberg AF, Lyons DM. Intranasal oxytocin administration attenuates the ACTH stress response in monkeys. Psychoneuroendocrinology 2005; 30: 924-929.
29. Kirsch P, Esslinger C, Chen Q, Mier D, Lis S, Siddhanti S, Gruppe H, Mattay VS, Gallhofer B, Meyer-Lindenberg A. Oxytocin modulates neural circuitry for social cognition and fear in humans. J Neurosci 2005; 25: 11489-11493.
30. Hollander E, Bartz J, Chaplin W, Phillips A, Sumner J, Soorya L, Anagnostou E, Wasserman S. Oxytocin increases retention of social cognition in autism. Biol Psychiatry 2007; 61: 498-503.
31. Hollander E, Novotny S, Hanratty M, Yaffe R, DeCaria CM, Aronowitz BR, Mosovich S. Oxytocin infusion reduces repetitive behaviors in adults with autistic and Asperger's disorders. Neuropsychopharmacology, 2003; 28: 193-198.
32. Harony H, Wagner S. The contribution of oxytocin and vasopressin to mammalian social behavior: potential role in autism spectrum disorder. Neurosignals 2010; 18: 82-97.
33. Meyer-Lindenberg A, Domes G, Kirsch P, Heinrich M. Oxytocin and vasopressin in the human brain: social neuropeptides for translational medicine. Nat Rev Neurosci 2011; 12: 524-538.
34. Striepens N, Kendrick KM, Maier W, Hurlemann R. Prosocial effects of oxytocin and clinical evidence for its therapeutic potential. Front Neuroendocrinol 2011; 32: 426-450.
35. Ellenbogen MA, Linnen AM, Grumet R, Cardoso C, Joober R. The acute effects of intranasal oxytocin on automatic and effortful attentional shifting to emotional faces. Psychophysiology 2012; 49: 128-137.
36. Ring RH. The central vasopressinergic system: examining the opportunities for psychiatric drug development. Curr Pharm Des 2005; 11: 205-225.
37. 1b vasopressin receptor in rat adrenal medulla. Endocrinology 1996; 137: 3906-3914.
38. Wisniewski K, Galyean R, Schteingart CD, Tariga H, Croston G, Alagarsamy S, Riviere PJM. Synthesis and in vitro characterization of new potent and selective oxytocin receptor agonist. In: Lebl M, Meldal M, Knud J, Jensen KJ, Høeg-Jensen T eds. Peptides 2010. Proc of the 31st European Peptide Symposium, The European Peptide Society, 2010: 306-307.
39. 1a receptor full agonist for the treatment of vasodilatory hypotension. J Pharmacol Exp Ther 2011; 337: 786-796.
40. 2 agonists. Eur J Med Chem 2009; 44: 2862-2867.
41. Magafa V, Borovicková L, Slaninová J, Cordopatis P. Synthesis and biological activity of oxytocin analogues containing unnatural amino acids in position 9: structure activity study. Amino Acids 2010; 38: 1549-1559.
42. Muttenthaler M, Andersson A, de Araujo AD, Dekan Z, Lewis RJ, Alewood PF. Modulating oxytocin activity and plasma stability by disulfide bond engineering. J Med Chem 2010; 53: 8585-8596.
43. Slusarz R, Slusarz MJ. An influence of the aromatic side chains conformations in positions 2 and 3 of vasopressin analogs on interactions with vasopressin and oxytocin receptors. QSAR Comb Sci 2009; 28: 1166-1175.
44. Manning M, Stoev S, Bankowski K. Peptides versus nonpeptides as therapeutics: an exiting challenge for Big Pharma. In: Lebl M, Meldal M, Jensen KJ, Hoeg-Jensen T, eds. Peptides 2010. Prompt Scientific Publishing: European Peptide Society, 2010: 366-367.
45. 1b receptor ligands. Prog Brain Res 2002; 139: 197-210.
46. Freidinger RM, Pettibone DJ. Small molecule ligands for oxytocin and vasopressin receptors. Med Res Rev 1997; 17: 1-16.
47. 1b vasopressin or oxytocin receptors. J Med Chem 2011; 54: 2864-2877.
48. Albizu L, Cottet M, Kralikova M, Stoev S, Seyer R, Brabet I, Roux T, Bazin H, Bourrier E, Lamarque L, Breton C, Rives ML, Newman A, Javitch J, Trinquet E, Manning M, Pin JP, Mouillac B, Durroux T. Time-resolved FRET between GPCR ligands reveals oligomers in native tissues. Nat Chem Biol 2010; 6: 587-594.
49. Stewart JM, Young JD. Solid Phase Synthesis. Rockford, IL: Pierce Chemical Company, 1984.
50. Holton PA. A modification of the method of Dale and Laidlaw for standardization of posterior pituitary extract. Br J Pharmacol 1948; 3: 328-334.
51. Schild HO. pA, a new scale of the measurement of drug antagonism. Br J Pharmacol Chemother 1947; 2: 189-206.
52. Dyckes DF, Nestor JJ Jr, Ferger MF, du Vigneaud V. [1-β-mercapto-β, β-diethylpropionic acid]-8-lysine vasopressin, a potent inhibitor of 8-lysine-vasopressin and of oxytocin. J Med Chem 1974; 17: 250-252.
53. Munsick RA. Effect of magnesium ion on the response of the rat uterus to neurohypophysial hormones and analogues. Endocrinology 1960; 66: 451-457.
54. Chan WY, Kelly N. A pharmacological analysis on the significance of the chemical functional groups of oxytocin to its oxytocic activity and on the effect of magnesium on the in vitro and in vivo oxytocic activity of neurohypophysial hormones. J Pharmacol Exp Ther 1967; 156: 150-158.
55. Dekanski J. The quantitative assay of vasopressin. Br J Pharmacol 1952; 7: 567-572.
56. Sawyer WH. Biologic assays for oxytocin and vasopressin. Methods Med Res 1961; 9: 210-219.
57. 1a vasopressin receptor. Nature 1992; 356: 523-526.
58. 1a vasopressin receptor. J Biol Chem 1994; 269: 3304-3310.
59. 1b vasopressin receptor. J Biol Chem 1994; 269: 27088-27092.
60. 3 pituitary vasopressin receptor. FEBS Lett 1994; 356: 215-220.
61. Birnbaumer M, Seibold A, Gilbert S, Ishido M, Barberis C, Antaramian A, Brabet P, Rosenthal W. Molecular cloning of the receptor for human antidiuretic hormone. Nature 1992; 357: 333-335.
62. 2 receptor and possible link to nephrogenic diabetes insipidus. Nature 1992; 357: 336-339.
63. Butlen D, Guillon G, Rajerison RM, Jard S, Sawyer WH, Manning M. Structural requirements for activation of vasopressin-sensitive adenylate cyclase, hormone binding, and antidiuretic actions: effects of highly potent analogues and competitive inhibitors. Mol Pharmacol 1978; 14: 1006-1017.
64. Kirk CJ, Guillon G, Balestre MN, Jard S. Stimulation, by vasopressin and other agonists, of inositol-lipid breakdown and inositol phosphate accumulation in WRK1 cells. Biochem J 1986; 240: 197-204.
65. Kimura T, Tanizawa O, Mori K, Brownstein M, Okayama H. Structure and expression of a human oxytocin receptor. Nature 1992; 356: 526-529.
66. 1-vasopressin and muscarinic cholinergic stimuli. Biochem J 1984; 221: 803-811.
67. Salomon Y, Londos C, Rodbell M. A highly sensitive adenylate cyclase assay. Anal Biochem 1974; 58: 541-548.
68. 1a vasopressin receptor agonist of high affinity. Br J Pharmacol 2002; 135: 1828-1836.
69. 1b receptors. Endocrinology 2002; 143: 4655-4664.
70. Guillon G, Pena A, Murat B, Derick S, Trueba M, Ventura MA, Szeto HH, Wo N, Stoev S, Cheng LL, Manning M. Position 4 analogues of [deamino-Cys1]arginine vasopressin exhibit striking species differences for human and rat V(2)/V(1b) receptor selectivity. J Pept Sci 2006; 12: 190-198.
71. 3H)-vasopressin binding to isolated rat hepatocytes and liver membranes: regulation by GTP and relation to glycogen phosphorylase activation. J Recept Res 1980; 1: 137-168.
72. 1b receptor based on modifications of deamino-[Cys1]arginine vasopressin at position 4. J Med Chem 2004; 47: 2375-2388.
73. 1b selective agonist for rat vasopressin/oxytocin receptors. Endocrinology 2007; 148: 4136-4146.
74. 1b receptor: based on modifications of deamino-[Cys1]arginine vasopressin at positions 4 and 8. J Med Chem 2007; 50: 835-847.
75. Lowbridge J, Manning M, Haldar J, Sawyer WH. Synthesis and some pharmacological properties of [4-threonine, 7-glycine]oxytocin, [1-(L-2-hydroxy-3-mercaptopropanoic acid), 4-threonine, 7-glycine]oxytocin (hydroxyl[Thr4, Gly7]oxytocin), and [7-glycine]oxytocin, peptides with high oxytocic-antidiuretic selectivity. J Med Chem 1977; 20: 120-123.
76. Lee AG, Cool DR, Grunwald WC Jr, Neal DE, Buckmaster CL, Cheng MY, Hyde SA, Lyons DM, Parker KJ. A novel form of oxytocin in New World monkeys. Biol Lett 2011; 7: 584-587.
77. Gutkowska J, Jankowski M. Oxytocin re-visited: its role in cardiovascular regulation. J Neuroendocrinol 2011; 24: 599-608.
78. Danalache BA, Gutkowska J, Slusarz MJ, Berezowska I, Jankowski M. Oxytocin-Gly-Lys-Arg: a novel cardiomyogenic peptide. PLoS ONE 2010; 5: e13643.
79. Sawyer WH, Acosta M, Balaspiri L, Judd J, Manning M. Structural changes in the arginine vasopressin, molecule that enhance antidiuretic activity and specificity. Endocrinology 1974; 94: 1106-1115.
80. Zaoral M, Kolc J, Sorm F. Amino acids and peptides. LXXI. Synthesis of 1-deamino-8-D-γ-aminobutyrine-vasopressin. 1-deamino-8-D-lysine-vasopressin, and 1-deamino-8-D-arginine-vasopressin. Coll Czech Chem Comm 1967; 32: 1250-1257.
81. Huguenin RL. Synthèse de la Phe2-Orn8-ocytocine, deux analogues de la vasopressine douse d'une activité pressorique selective. Helv Chim Acta 1964; 47: 1934-1941.
82. Aurell C-J, Bengtsson B, Ekholm K, Kasprzykowska R, Nilson A, Person R, Trojnar J, Abbe M, Melin P. Development of vasopressor specific analogues with prolonged effects. In: Giralt E, Andreu D eds. Peptides 1990. Proc of the 21European Peptide Symposium. Leiden: ESCOM Science Publishers, 1991: 671-673.
83. 1a receptor agonists. J Med Chem 2011; 54: 4388-4398.
84. Manning M, Coy EJ, Sawyer WH, Acosta M. Solid-phase synthesis and some pharmacological properties of 4-threonine analogs of vasopressins and vasotocin and of arginine-vasopressin and arginine-vasotocin. J Med Chem 1973; 16: 463-466.
85. Boissonnas RA, Guttmann S. Synthese d'analogues de l'oxytocine et de la lysine-vasopressine contenant de la phenylalanine ou de la tyrosine en position 2 et 3. Helv Chim Acta 1960; 43: 190-200.
86. 1b receptors. In: Rolka K, Rekowski P, Silberring J, eds. Peptides 2006. Geneva: Kenes International, 2007: 742-743.
87. Dyckes DF, Ferger MF, du Vigneaud V. Synthesis and some of the pharmacological properties of (4-leucine)-8-lysine-vasopressin and (1-deamino, 4-leucine)-8-lysine-vasopressin. J Med Chem 1973; 16: 843-847.
88. 1b vasopressin receptor: evidence for its expression in extra-pituitary tissues. Biochem Biophys Res Commun 1995; 26: 751-757.
89. 1b/oxytocin receptor antagonist. Br J Pharmacol 2005; 146: 744-751.
90. Roper JA, O'Carroll A-M, Young WS III, Lolait SJ. The vasopressin Avprib receptor: molecular and pharmacological studies. Stress 2011; 14: 98-115.
91. Kruszynski M, Lammek B, Manning M, Seto J, Haldar J, Sawyer WH. [1-beta-Mercapto-beta, beta-cyclopentamethylenepropionic acid), 2-(O-methyl)tyrosine] arginine-vasopressin and [1-beta-mercapto-beta, beta-cyclopentamethylenepropionic acid)]argine-vasopressine, two highly potent antagonists of the vasopressor response to arginine-vasopressin. J Med Chem 1980; 23: 364-368.
92. 1a receptor antagonists: new approaches for the design of potential tocolytics for preterm labor. J Pharmacol Exp Ther 1996; 227: 999-1003.
93. Manning M, Przybylski JP, Olma A, Klis WA, Kruszynski M, Wo NC, Pelton GH, Sawyer WH. No requirement of cyclic conformation of antagonists in binding to vasopressin receptors. Nature 1987; 329: 839-840.
94. Manning M, Nawrocka E, Misicka A, Olma A, Klis WA, Seto J, Sawyer WH. Potent and selective antagonists of the antidiuretic responses to arginine-vasopressin based on modifications of [1-(beta-mercapto-β, β-pentamethylenepropionic acid), 2-D-isoleucine, 4-valine]arginine-vasopressin at position 4. J Med Chem 1984; 27: 423-429.
95. 1) responses to vasopressin. Int J Pept Protein Res 1988; 32: 455-467.
96. 1a receptor antagonists of vasopressin. Int J Pept Protein Res 1992; 40: 261-267.
97. 1a receptors. Neuroendocrinology 1995; 62: 135-146.
98. Manning M, Olma A, Klis WA, Kolodziejczyk AM, Seto J, Sawyer WH. Design of more potent antagonists of the antidiuretic responses to arginine-vasopressin. J Med Chem 1982; 25: 45-50.
99. 1) receptors. J Med Chem 1987; 30: 2245-2252.
100. 2 vasopressin antagonists with structural changes at their C-terminals. Peptides 1988; 9: 157-163.
101. 1a vasopressin antagonists with C-terminal ethylenediamine-linked retro-amino acids. J Med Chem 1992; 35: 3895-3904.
102. Akerlund M. Targeting the oxytocin receptor to relax the myometrium. Expert Opin Ther Targets. 2006; 10: 423-427.
103. Bankowski K, Manning M, Seto J, Haldar J, Sawyer WH. Design and synthesis of potent in vivo antagonists of oxytocin. Int J Pept Prot Res 1980; 16: 382-391.
104. Manning M, Miteva K, Pancheva S, Stoev S, Wo NC, Chan WY. Design and synthesis of highly selective in vitro and in vivo uterine receptor antagonists of oxytocin: comparisons with atosiban. Int J Peptide Protein Res 1995; 46: 244-252.
105. 4, Tyr-NH29]OVT: a selective oxytocin receptor ligand. Eur J Pharmacol 1988; 147: 197-207.
106. Melin P, Trojnar J, Johansson B, Vilhardt H, Akerlund M. Synthetic antagonists of the myometrial response to vasopressin and oxytocin. J Endocrinol 1986; 111: 125-131.
107. 1 receptor antagonist. Science 1991; 252: 572-574.
108. 2-receptor antagonist: pharmacological profile and aquaretic effect by single and multiple oral dosing in rats. J Pharmacol Exp Ther 1998; 287: 860-867.
109. 2-receptor antagonist, for hyponatremia. N Engl J Med 2006; 355: 2099-2112.
110. 2 receptor antagonist, in vitro and in vivo. J Pharmacol Exp Ther 1997; 282: 301-308.
111. Ghali JK, Tam SW. The critical link of hypervolemia and hyponatremia in heart failure and the potential role of arginine vasopressin antagonists. J Card Fail 2010; 16: 419-431.
112. Robertson GL. Vaptans for the treatment of hyponatremia. Nat Rev Endocrinol 2011; 7: 151-161.
113. Gross PA, Wagner A, Decaux G. Vaptans are not the mainstay of treatment in hyponatremia: perhaps not yet. Kidney Int 2011; 80: 594-600.
114. Verbalis JG, Adler S, Schrier RW, Berl T, Zhao Q, Czerwiec FS; SALT Investigators. Efficacy and safety of oral tolvaptan therapy in patients with the syndrome of inappropriate antidiuretic hormone secretion. Eur J Endocrinol 2011; 164: 725-732.
115. Ferguson-Myrthil N. Novel agents for the treatment of hyponatremia: a review of conivaptan and tolvaptan. Cardiol Rev 2010; 18: 313-321.
116. 1a receptors. J Clin Invest 1993; 92: 224-231.
117. 1a receptor inhibition improves neurologic outcomes following an intracerebral hemorrhagic brain injury. Neurochem Int 2011; 58: 542-548.
118. Russell R, Doyle R, Turner J, Attkins N, Ramsey S, Weibley L, Bateman L, Bictash M, Neal-Morgan S, Ivarsson M, Pullen N. In vitro and in vivo pharmacological characterisation of the potent and selective vasopressin V(1a) receptor antagonist 4-[4-(4-chloro-phenyl)-5-[1, 2, 3]triazol-2-ylmethyl-4H-[1, 2, 4]triazol-3-yl]-piperidin-1-yl-(3, 5-difluoro-phenyl) methanone (PF-00738245). Eur J Pharmacol 2011; 670: 347-355.
119. 11C]SSR149415 and preliminary imaging studies using positron emission tomography. Bioorg Med Chem Lett 2010; 20: 3103-3106.
120. 1b receptor. Physiol Behav 2011; 103: 393-403.
121. Zmily HD, Daifallah S, Ghali JK. Tolvaptan, hyponatremia, and heart failure. Int J Nephrol Renovasc Dis 2011; 4: 57-71.
122. Pang PS, Gheorghiade M, Dihu J, Swedberg K, Khan S, Maggioni AP, Grinfeld L, Zannad F, Burnett JC Jr, Ouyang J, Udelson JE, Konstam MA. Effects of tolvaptan on physician-assessed symptoms and signs in patients hospitalized with acute heart failure syndromes: analysis from the efficacy of vasopressin antagonism in heart failure outcome study with tolvaptan (EVEREST) trials. Am Heart J 2011; 161: 1067-1072.
123. Gassanov N, Semmo N, Semmo M, Nia AM, Fuhr U, Er F. Arginine vasopressin (AVP) and treatment with arginine vasopressin receptor antagonists (vaptans) in congestive heart failure, liver cirrhosis and syndrome of inappropriate antidiuretic hormone secretion (SIADH). Eur J Clin Pharmacol 2011; 67: 333-346.
124. 2 receptor antagonist. J Clin Invest 1996; 98: 2729-2738.
125. Rochdi MD, Vargas GA, Carpentier E, Oligny-Longpré G, Chen S, Kovoor A, Gitelman SE, Rosenthal SM, von Zastrow M, Bouvier M. Functional characterization of vasopressin type 2 receptor substitutions (R137H/C/L) leading to nephrogenic diabetes insipidus and nephrogenic syndrome of inappropriate antidiuresis: implications for treatments. Mol Pharmacol 2010; 77: 836-845.
126. Ranadive SA, Ersoy B, Favre H, Cheung CC, Rosenthal SM, Miller WL, Vaisse C. Identification, characterization and rescue of a novel vasopressin-2 receptor mutation causing nephrogenic diabetes insipidus. Clin Endocrinol (Oxf) 2009; 71: 388-393.
127. 2 receptor antagonist. Br J Pharmacol 1992; 105: 787-791.
128. Naidech AM, Paparello J, Liebling SM, Bassin SL, Levasseur K, Alberts MJ, Bernstein RA, Muro K. Use of Conivaptan (Vaprisol) for hyponatremic neuro-ICU patients. Neurocrit Care 2010; 13: 57-61 Erratum in: Neurocrit Care 2011; 15: 210.
129. Velez JC, Dopson SJ, Sanders DS, Delay TA, Arthur JM. Intravenous conivaptan for the treatment of hyponatraemia caused by the syndrome of inappropriate secretion of antidiuretic hormone in hospitalized patients: a single-centre experience. Nephrol Dial Transplant 2010; 25: 1524-1531.
130. Williams PD, Clineschmidt BV, Erb JM, Freidinger RM, Guidotti MT, Lis EV, Pawluczyk JM, Pettibone DJ, Reiss DR, Veber DF, Woyden CY. 1-(1-[(N-acetyl-4-piperidinyl)oxy]-2-methoxybenzoyl]piperidin-4-yl)-4H-3, 1-benzoxazin-2(1H)-one (L-371-257): a new, orally bioavailable, non-peptide oxytocin antagonist. J Med Chem 1995; 38: 4634-4636.
131. Ring RH, Malberg JE, Potestio L, Ping J, Boikess S, Luo B, Schechter LE, Rizzo S, Rahman Z, Rosenzweig-Lipson S. Anxiolytic-like activity of oxytocin in male mice: behavioral and autonomic evidence, therapeutic implications. Psychopharmacology 2006; 185: 218-225.
132. Liddle J, Allen MJ, Borthwick AD, Brooks DP, Davies DE, Edwards RM, Exall AM, Hamlett C, Irving WR, Mason AM, McCafferty GP, Nerozzi F, Peace S, Philp J, Pollard D, Pullen MA, Shabbir SS, Sollis SL, Westfall TD, Woollard PM, Wu C, Hickey DM. The discovery of GSK221149A: a potent and selective oxytocin antagonist. Bioorg Med Chem Lett 2008; 18: 90-94.
133. Borthwick AD. Oral oxytocin antagonists. J Med Chem 2010; 53: 6525-6538.
134. Wootten DL, Simms J, Massoura AJ, Trim JE, Wheatley M. Agonist-specific requirement for a glutamate in transmembrane helix 1 of the oxytocin receptor. Mol Cell Endocrinol 2011; 333: 20-27.
135. Smith AS, Agmo A, Birnie AK, French JA. Manipulation of the oxytocin system alters social behavior and attraction in pair-bonding primates, Callithrix penicillata. Horm Behav 2010; 57: 255-262.
136. Olszewski PK, Klockars A, Olszewska AM, Fredriksson R, Schiöth HB, Levine AS. Molecular, immunohistochemical, and pharmacological evidence of oxytocin's role as inhibitor of carbohydrate but not fat intake. Endocrinology 2010; 151: 4736-4744.
137. Frantz MC, Rodrigo J, Boudier L, Durroux T, Mouillac B, Hibert M. Subtlety of the structure-affinity and structure-efficacy relationships around a nonpeptide oxytocin receptor agonist. J Med Chem 2010; 53: 1546-1562.
138. Ring RH, Schechter LE, Leonard SK, Dwyer JM, Platt BJ, Graf R, Grauer S, Pulicicchio C, Resnick L, Rahman Z, Sukoff Rizzo SJ, Luo B, Beyer CE, Logue SF, Marquis KL, Hughes ZA, Rosenzweig-Lipson S. Receptor and behavioral pharmacology of WAY-267464, a non-peptide oxytocin receptor agonist. Neuropharmacology 2010; 58: 69-77.
139. Insel TR. The challenge of translation in social neuroscience: a review of oxytocin, vasopressin, and affiliative behavior. Neuron 2010; 65: 768-779.
140. Rahman Z, Resnick L, Rosenzweig-Lipton SJ, Ring RH. Methods of treatment using oxytocin receptor agonists US Patent 20070117794, Kind Code: A1, Publication date 10/24/2007.
141. Beyer CE, Dwyer JM, Platt BJ, Neal S, Luo B, Ling HP, Lin Q, Mark RJ, Rosenzweig-Lipson S, Schechter LE. Angiotensin IV elevates oxytocin levels in the rat amygdala and produces anxiolytic-like activity through subsequent oxytocin receptor activation. Psychopharmacology 2010; 209: 303-311.
142. Jard S, Gaillard RC, Guillon G, Marie J, Schoenenberg P, Muller AF, Manning M, Sawyer WH. Vasopressin antagonists allow demonstration of a novel type of vasopressin receptor in the rat adenohypophysis. Mol Pharmacol 1986; 30: 171-177.
143. Pradelles P, Morgat JL, Fromageot P, Camier M, Bonne D, Cohen P, Bockaert J, Jard S. Tritium labelling of 8-lysine vasopressin and its purification by affinity chromatography on sepharose bound neurophysins. FEBS Lett 1972; 26: 189-192.
144. Berridge MJ, Irvine RF. Inositol trisphosphate, a novel second messenger in cellular signal transduction. Nature 1984; 312: 315-321.
145. 3H)lysine-vasopressin to pig kidney plasma membranes. Relationship of receptoroccupancy to adenylate cyclase activation. J Biol Chem 1973; 248: 5922-5931.
146. 1a receptors. J Med Chem 2002; 45: 2579-2588.
147. 1b receptor ligand. Am J Physiol Regul Integr Comp Physiol 2007; 293: R938-R949.
148. Thibonnier M, Preston JA, Dulin N, Wilkins PL, Berti-Mattera LN, Mattera R. The human V3 pituitary vasopressin receptor: ligand binding profile and density-dependent signaling pathways. Endocrinology 1997; 138: 4109-4122.
149. 1a receptor. Evidence for a major localization within transmembrane regions. J Biol Chem 1995; 270: 25771-25777.
150. 1b receptors: a combined pharmacological/knockout approach. Mol Pharmacol 2004; 65: 623-629.
151. Chini B, Mouillac B, Balestre MN, Trumpp-Kallmeyer S, Hoflack J, Hibert M, Andriolo M, Pupier S, Jard S, Barberis C. Two aromatic residues regulate the response of the human oxytocin receptor to the partial agonist arginine vasopressin. FEBS Lett 1996; 397: 201-206.
152. Tahara A, Saito M, Sugimoto T, Tomura Y, Wada K, Kusayama T, Tsukada J, Ishii N, Yatsu T, Uchida W, Tanaka A. Pharmacological characterization of the human vasopressin receptor subtypes stably expressed in Chinese hamster ovary cells. Br J Pharmacol 1998; 125: 1463-1470.
153. 3H]-[Thr4, Gly7]OT: a highly selective ligand for central and peripheral OT receptors. Am J Physiol 1988; 254: E31-E38.
154. 1a vasopressin receptor. EMBO J 1995; 14: 2176-2182.
155. Andrés M, Peña A, Derick S, Raufaste D, Trojnar J, Wisniewski K, Trueba M, Serradeil-Le Gal C, Guillon G. Comparative pharmacology of bovine, human and rat vasopressin receptor isoforms. Eur J Pharmacol 2004; 501: 59-69.
156. Chini B, Manning M. Agonist selectivity in the oxytocin/vasopressin receptor family: new insights and challenges. Biochem Soc Trans 2007; 35: 737-741.
157. Chini B, Manning M, Guillon G. Affinity and efficacy of selective agonists and antagonists for vasopressin and oxytocin receptors: an 'easy guide' to receptor pharmacology. Prog Brain Res 2008; 170: 513-517.
158. Sala M, Braida D, Lentini D, Busnelli M, Bulgheroni E, Capurro V, Finardi A, Donzelli A, Pattini L, Rubino T, Parolaro D, Nishimori K, Parenti M, Chini B. Pharmacologic rescue of impaired cognitive flexibility, social deficits, increased aggression, and seizure susceptibility in oxytocin receptor null mice: a neurobehavioral model of autism. Biol Psychiatry 2011; 69: 875-882.
159. 1a receptors reveal surprising species differences. In: Martinez J, Fehrentz JA, eds. Peptides 2000. Paris: EDK, Editions Medicales et Scientifiques, 2001: 589-590.
160. Manning M, Cheng LL, Stoev S, Wo NC, Chan WY, Szeto HH, Durroux T, Mouillac B, Barberis C. Design of peptide oxytocin antagonists with strikingly higher affinities and selectivities for the human oxytocin receptor than atosiban. J Pept Sci 2005; 11: 593-608.
161. Serradeil-Le Gal C, Valette G, Foulon L, Germain G, Advenier C, Naline E, Bardou M, Martinolle JP, Pouzet B, Raufaste D, Garcia C, Double-Cazanave E, Pauly M, Pascal M, Barbier A, Scatton B, Maffrand JP, Le Fur G. SSR126768A (4-chloro-3-[(3R)-(+)-5-chloro-1-(2, 4-dimethoxybenzyl)-3-methyl-2-oxo-2, 3-dihydro-1H-indol-3-yl]-N-ethyl-N-(3-pyridylmethyl)-benzamide, hydrochloride): a new selective and orally active oxytocin receptor antagonist for the prevention of preterm labor. J Pharmacol Exp Ther 2004; 309: 414-424.
162. Schmidt A, Audigier S, Barberis C, Jard S, Manning M, Kolodziejczyk AS, Sawyer WH. A radioidinated linear vasopresin antagonist. FEBS 1991; 282: 77-81.
163. Jasper JR, Harrell CM, O'Brien JA, Pettibone DJ. Characterization of the human oxytocin receptor stably expressed in 293 human embryonic kidney cells. Life Sci 1995; 57: 2253-2261.
164. 1b receptor antagonist. J Pharmacol Exp Ther 2002; 300: 1122-1130.
165. Peters MF, Vaillancourt F, Heroux M, Valiquette M, Scott CW. Comparing label-free biosensors for pharmacological screening with cell-based functional assays. Assay Drug Dev Technol 2010; 8: 219-227.
166. Busnelli M, Sauliere A, Manning M, Bouvier M, Gales C, Chini B. Functional selective oxytocin-derived agonists discriminate between individual G protein family subtypes. J Biol Chem 2012; 287: 3617-3629.
167. Caldwell HK, Lee H-J, Macbeth AH, Young WS 3rd. Vasopressin: behavioral roles of an original neuropeptide. Prog in Neurobiol 2008; 84: 1-24.
168. 1 vasopressin receptors. J Recept Res 1989; 9: 27-41.
169. Tribollet E, Goumaz M, Raggenbass M, Dreifuss JJ. Appearance and transient expression of vasopressin and oxytocin receptors in the rat brain. J Recept Res 1991; 11: 333-346.
170. 1b receptor in the rat brain and pituitary gland: anatomical support for its involvement in the central effects of vasopressin. Endocrinology 2001; 142: 1659-1668.
171. 2, vasopressin receptor genes are expressed in the supraoptic nucleus of the rat hypothalamus, and the transcripts are essentially colocalized in the vasopressinergic magnocellular neurons. Endocrinology 1998; 139: 4701-4707.
172. Hurbin A, Dubrez L, Coll JL, Favrot MC. The vasopressin receptors colocalize with vasopressin in the magnocellular neurons of the rat supraoptic nucleus and are modulated by water balance. Endocrinology 2002; 143: 456-466.
173. Young WS, Li J, Wersinger SR, Palkovits M. The vasopressin 1b receptor is prominent in the hippocampal area CA2 where it is unaffected by restraint stress or adrenalectomy. Neuroscience 2006; 143: 1031-1039.
174. Mouillac B, Manning M, Durroux T. Fluorescent agonists and antagonists for vasopressin/oxytocin G protein-coupled receptors: usefulness in ligand screening assays and receptor studies. Mini Rev Med Chem 2008; 8: 996-1005.
175. Taki M, Hohsaka T, Murakami H, Taira K, Sisido M. A non-natural amino acid for efficient incorporation into proteins as a sensitive fluorescent probe. FEBS Lett 2001; 507: 35-38.
176. Panchuk-Voloshina N, Haugland RP, Bishop-Stewart J, Bhalgat MK, Millard PJ, Mao F, Leung W-Y, Huagland R. Alexa dyes, a series of new fluorescent dyes that yield exceptionally bright, photostable conjugates. J Histochem Cytochem 1999; 47: 1179-1188.
177. Ballard JL, Peeva VK, deSilva CJ, Lynch JL, Swanson NR. Comparison of Alexa Fluor and Cy Dye for practical DNA microarray use. Mol Biotechnol 2007; 36: 175-183.
178. Durroux T, Peter M, Turcatti G, Cholet A, Balestre MN, Barberis C, Seyer R. Fluorescent pseudo-peptide linear vasopressin antagonists: design, synthesis and applications. J Med Chem 2009; 42: 1312-1319.
179. Kirk KL, Buku A, Eggena P. Cell specificity of vasopressin binding in renal collecting duct: computer-enhanced imaging of a fluorescent hormone analog. Proc Natl Acad Sci USA 1987; 84: 6000-6004.
180. Bonnet D, Riché S, Loison S, Dagher R, Frantz MC, Boudier L, Rameh R, Mouillac B, Haiech J, Hibert M. Solid-phase organic tagging resins for labeling biomolecules by 1, 3-dipolar cycloaddition: application to the synthesis of a fluorescent non-peptidic vasopressin recptor ligand. Chemistry 2008; 14: 6247-6254.
181. Maurel D, Kniazeff J, Mathis G, Trinquet E, Pin JP, Ansanay H. Cell surface detection of membrane protein interaction with homogeneous time-resolved fluorescence resonance energy transfer technology. Anal Biochem 2004; 329: 253-262.
182. Milligan G, Bouvier M. Methods to monitor the quaternary structure of G protein-coupled receptors. FEBS J 2005; 272: 2914-2925.
183. Albizu L, Balestre MN, Breton C, Pin JP, Manning M, Mouillac B, Barberis C, Durroux T. Probing the existence of G protein-coupled recptor dimers by positive and negative ligand-dependent cooperative binding. Mol Pharmacol 2006; 70: 1783-1791.
184. 1b receptor through compartmentalization within the plasma membrane. Mol Pharmacol 2009; 75: 637-647.
185. 2 receptors form constitutive homo- and heterodimers during biosynthesis. Mol Endocrinol 2003; 17: 677-691.
186. Devost D, Zingg HH. Homo- and hetero-dimeric complex formations of the human oxytocin receptor. J Neuroendocrinol 2004; 16: 372-377.
187. Pin JP, Maurel D, Comps-Agrar L, Monnier C, Rives A-L, Doumazane E, Rondard P, Durroux T, Prezeau L, Trinquet E. Time-resolved FRET approaches to study GPCRs complexes: In: Siehler S, Milligan G, eds. G Protein-Coupled Receptors; Structure, Signaling and Physiology. Cambridge: Cambridge University Press, 2011: 67-90.
188. Albizu L, Teppaz G, Seyer R, Bazin H, Ansanay H, Manning M, Mouillac B, Durroux T. Toward efficient drug screening by homogeneous assays based on the development of new fluorescent vasopressin and oxytocin receptor ligands. J Med Chem 2007; 50: 4976-4985.
189. Zwier JM, Roux T, Cottet M, Durroux T, Douzon S, Bdioui S, Gregor N, Bourrier E, Oueslati N, Nicolas L, Tinel N, Boisseau C, Yverneau P, Charrier-Savournin F, Fink M, Trinquet E. A fluorescent ligand-binding alternative using Tag-lite(R) Technology. J Biomol Screen 2010; 15: 1248-1259.
190. Cottet M, Faklaris O, Zwier JM, Trinquet E, Pin J-P, Durroux T. Original fluorescent ligand-based assays open new perspectives in G-protein coupled receptor drug screening. Pharmaceuticals 2011; 4: 202-214.
191. Deblon N, Veyrat-Durebex C, Bourgoin L, Caillon A, Bussier AL, Petrosino S, Piscitelli F, Legros JJ, Geenen V, Foti M, Wahli W, Di Marzo V, Rohner-Jeanrenaud F. Mechanisms of the anti-obesity effects of oxytocin in diet-induced obese rats. PLoS ONE 2011; 6: e25565.
192. Sterns R, Hix J. Hyponatremia: vasopressin antagonists in hyponatremia: more data needed. Nat Rev Nephrol 2011; 7: 132-133.
193. Vlieghe P, Lisowski V, Martinez J, Khrestchatisky JM. Synthetic therapeutic peptides: science and market. Drug Discovery Today 2010; 15: 40-56.
194. Reichert J. Development Trends for Peptide Therapeutics. Peptide Therapeutics Foundation, 2010 Report,.
195. Assinder SJ. Oxytocin increases 5alpha-reductase activity of human prostate epithelial cells, but not stromal cells. Prostate 2008; 68: 115-121.
196. Beery AK, Zucker I. Oxytocin and same-sex social behavior in female meadow voles. Neuroscience 2010; 169: 665-673.
197. Bosch OJ, Neumann ID. Both oxytocin and vasopressin are mediators of maternal care and aggression in rodents: from central release to sites of action. Horm Behav 2011; Doi: [Epub before print].
198. Braida D, Donzelli A, Martucci R, Capurro V, Busnelli M, Chini B, Sala M. Neurohypophyseal hormones manipulation modulate social and anxiety-related behavior in zebrafish. Psychopharmacology 2012; 220: 319-330.
199. Breton J-D, Veinante P, Uhl-Bronner S, Vergnano AM, Freund-Mercier MJ, Schlichter R, Poisbeau P. Oxytocin-induced antinoiception in the spinal cord is mediated by subpopulation of glutamatergic neurons in lamina I-II which amplify GABAergic inhibition. Molecular Pain 2008; 4: 19-31.
200. Figueira RJ, Peabody MF, Lonstein JS. Oxytocin receptor activity in the ventrocaudal periaqueductal gray modulates anxiety-related behavior in postpartum rats. Behav Neurosci 2008; 122: 618-628.
201. 1a receptors and not oxytocin receptors. Br J Pharmacol 2008; 155: 118-126.
202. Israel JM, Poulain DA, Oliet SH. Oxytocin-induced postinhibitory rebound firing facilitates bursting activity in oxytocin neurons. J Neurosci 2008; 28: 385-394.
203. Karavashkina TA, Kutina AV, Shakhmatova EI, Natochin YV. Mechanism of 1-deamino-arginine vasotocin induced natriuresis in rats. Gen Comp Endocrinol 2011; 170: 460-467.
204. Karelina K, Stuller KA, Jarrett B, Zhang N, Wells J, Norman GJ, Devries AC. Oxytocin mediates social neuroprotection after cerebral ischemia. Stroke 2011; 42: 3606-3611.
205. Kennett JE, Poletini MO, Fitch CA, Freeman ME. Antagonism of oxytocin prevents suckling- and estradiol-induced, but not progesterone-induced, secretion of prolactin. Endocrinology 2009; 150: 2292-2299.
206. Kim JS, Kim WB, Kim YB, Lee Y, Kim YS, Shen FY, Lee SW, Park D, Choi HJ, Hur J, Park JJ, Han HC, Colwell CS, Cho YW, Kim YI. Chronic hyperosmotic stress converts GABAergic inhibition into excitation in vasopressin and oxytocin neuronsin the rat. J Neurosci 2011; 31: 13312-13322.
207. Lee H-J, Macbeth AH, Pagani J, Young WS III. Oxytocin: the great facilitator of life. Prog Neurobiol 2009; 88: 127-151.
208. Lukas M, Toth I, Reber SO, Slattery DA, Veenema AH, Neumann ID. The neuropeptide oxytocin facilitates pro-social behavior and prevents social avoidance in rats and mice. Neuropsychopharmacology 2011; 36: 2159-2168.
209. Macciò A, Madeddu C, Chessa P, Panzone F, Lissoni P, Mantovani G. Oxytocin both increases proliferative response of peripheral blood lymphomonocytes to phytohemagglutinin and reverses immunosuppressive estrogen activity. In Vivo 2010; 24: 157-163.
210. Mak P, Broussard C, Vacy K, Broadbear JH. Modulation of anxiety behavior in the elevated plus maze using peptidic oxytocin and vasopressin receptor ligands in the rat. J Psychopharmacol 2011 PubMed PMID: 21890582.
211. 1b receptor deficiency on adrenocorticotropin release from anterior pituitary cells in responce to oxytocin stimulation. Endocrinology 2008; 149: 4883-4891.
212. Neumann ID, Veenema AH, Beiderbeck DI. Aggression and anxiety: social context and neurobiological links. Front Behav Neurosci 2010; 4: 12-28.
213. Norman GJ, Karelina K, Morris JS, Zhang N, Cochran M, Courtney DeVries A. Social interaction prevents the development of depressive-like behavior postnerve injury in mice: a potential role for oxytocin. Psychosom Med 2010; 72: 519-526.
214. Northrop LE, Erskine MS. Selective oxytocin receptor activation in the ventrolateral portion of the ventromedial hypothalamus is required for mating-induced pseudopregnancy in the female rat. Endocrinology 2008; 149: 836-842.
215. Nyuyki KD, Waldherr M, Baeuml S, Neumann ID. Yes, i am ready now: differential effects of paced versus unpaced mating on anxiety and central oxytocin release in female rats. PLoS ONE 2011; 6: e23599.
216. Oldfield RG, Hofmann HA. Neuropeptide regulation of social behavior in a monogamous cichlid fish. Physiol Behav 2011; 102: 296-303.
217. Saito A, Nakamura K. Oxytocin changes primate paternal tolerance to offspring in food transfer. J Comp Physiol A Neuroethol Sens Neural Behav Physiol 2011; 197: 329-337.
218. Schorscher-Petcu A, Sotocinal S, Ciura S, Dupré A, Ritchie J, Sorge RE, Crawley JN, Hu SB, Nishimori K, Young LJ, Tribollet E, Quirion R, Mogil JS. Oxytocin-induced analgesia and scratching are mediated by the vasopressin-1A receptor in the mouse. J Neurosci 2010; 30: 8274-8284.
219. Schorscher-Petcu A, Dupre A, Tribollet E. Distribution of vasopressin and oxytocin binding sites in the brain and upper spinal cord of the common marmoset. Neurosci Lett 2009; 461: 217-222.
220. Shirley DG, Walter MF, Keeler BD, Waters NJ, Walter SJ. Selective blockade of oxytocin and vasopressin V(1a) receptors in anaesthetised rats: evidence that activation of oxytocin receptors rather than V(1a) receptors increases sodium excretion. Nephron Physiol 2011; 117: 21-26.
221. Slattery DA, Neumann ID. Chronic icv oxytocin attenuates the pathological high anxiety state of selectively bred Wistar rats. Neuropharmacology 2010; 58: 56-61.
222. Takada M, Fujimaki-Aoba K, Hokari S. Vasotocin- and mesotocin-induced increases in short-circuit current across tree frog skin. J Comp Physiol B 2011; 181: 239-248.
223. Teruyama R, Lipschitz DL, Wang L, Ramoz GR, Crowley WR, Bealer SL, Armstrong WE. Central blockade of oxytocin receptors during mid-late gestation reduces amplitude of slow afterhyperpolarization in supraoptic oxytocin neurons. Am J Physiol Endocrinol Metab 2008; 295: E1167-E1171.
224. Timmer M, Cordero MI, Sevelinges Y, Sandi C. Evidence for a role of oxytocin receptors in the long-term establishment of dominance hierarchies. Neuropsychopharmacology 2011; 36: 2349-2356.
225. Veenema AH, Bredewold R, De Vries GJ. Vasopressin regulates social recognition in juvenile and adult rats of both sexes, but in sex- and age-specific ways. Horm Behav 2012; 61: 50-56.
226. Viero C, Shibuya I, Kitamura N, Verkhratsky A, Fujihara H, Katoh A, Ueta Y, Zingg HH, Chvatal A, Sykova E, Dayanithi G. REVIEW: Oxytocin: crossing the bridge between basic science and pharmacotherapy. CNS Neurosci Ther 2010; 16: e138-e156.
227. Viviani D, Charlet A, van den Burg E, Robinet C, Hurni N, Abatis M, Magara F, Stoop R. Oxytocin selectively gates fear responses through distinct outputs from the central amygdala. Science 2011; 333: 104-107.
228. Vrachnis N, Malamas FM, Sifakis S, Deligeoroglou E, Iliodromiti Z. The oxytocin-oxytocin receptor system and its antagonists as tocolytic agents. Int J Endocrinol 2011; 2011: 350546.
229. Waldherr M, Nyuyki K, Maloumby R, Bosch OJ, Neumann ID. Attenuation of the neuronal stress responsiveness and corticotrophin releasing hormone synthesis after sexual activity in male rats. Horm Behav 2010; 57: 222-229.
230. Wrobel LJ, Reymond-Marron I, Dupré A, Raggenbass M. Oxytocin and vasopressin enhance synaptic transmission in the hypoglossal motor nucleus of young rats by acting on distinct receptor types. Neuroscience 2010; 165: 723-735.
231. Yang J, Pan YJ, Zhao Y, Qiu PY, Lu L, Li P, Chen F, Yan XQ, Wang DX. Oxytocin in the rat caudate nucleus influences pain modulation. Peptides 2011; 32: 2104-2107.
232. Busnardo C, Tavares RF, Correa FM. Mechanisms involved in the pressor response to noradrenaline microinjection into the supraoptic nucleus of unanesthetized rats. Auton Neurosci 2009; 145: 63-70.
233. Chen J, Young S, Subburaju S, Sheppard AK, Atkinson H, Wood S, Lightman S, Serradeil-Le Gal C, Aguilera G. Vasopressin does not mediate hypersensivity of the hypothalamic pituitary adrenal axis during chronic stress. stress, neurotransmitters, and hormones. Ann NY Acad Sci 2008; 1148: 349-359.
234. Cudnoch-Jedrzejewska A, Szczepanska-Sadowska E, Dobruch J, Gomolka R, Puchalska L. Brain vasopressin V(1) receptors contribute to enhanced cardiovascular responses to acute stress in chronically stressed rats and rats with myocardial infarction. Am J Physiol Regul Integr Comp Physiol 2010; 298: R672-R680.
235. Dutertre S, Croker D, Daly NL, Andersson A, Muttenthaler M, Lumsden NG, Craik DJ, Alewood PF, Guillon G, Lewis RJ. Conopressin-T from Conus tulipa reveals an antagonist switch in vasopressin-like peptides. J Biol Chem 2008; 283: 7100-7108.
236. Goel M, Zuo CD, Schilling WP. Role of cAMP/PKA signalling cascade in vasopressin-induced trafficking of TRPC3 channels in principal cells of the collecting duct. Am J Physiol Renal Physiol 2010; 298: F988-F996.
237. Koshimizu TA, Tsujimoto G. New topics in vasopressin receptors and approach to novel drugs: vasopressin and pain perception. J Pharmacol Sci 2009; 109: 33-37.
238. Kublaoui BM, Gemelli T, Tolson KP, Wang Y, Zinn AR. Oxytocin deficiency mediates hyperphagic obesity of Sim1 haploinsufficient mice. Mol Endocrinol 2008; 22: 1723-1734.
239. Louiset E, Contesse V, Groussin L, Cartier D, Duparc C, Perraudin V, Bertherat J, Lefebvre H. Expression of vasopressin receptors in ACTH-independent macronodular bilateral adrenal hyperplasia causing Cushing's syndrome: molecular, immunohistochemical and pharmacological correlates. J Endocrinol 2008; 196: 1-9.
240. 2-receptor-antagonism in septic shock: a randomized, controlled, experimental study. Crit Care 2010; 14: R200.
241. Rodriguez-Borrero E, Rivera-Escalera F, Candelas F, Montalvo J, Munoz-Miranda WJ, Walker JR, Maldonado-Vlaar CS. Arginine vasopressin gene expression changes within the nucleus accumbens during environment elicited cocaine-conditioned response in rats. Neuropharmacology 2010; 58: 88-101.
242. 1a-like vasotocin receptors in a urodele amphibian, Taricha granulosa. Gen Comp Endocrinol 2011; 170: 131-143.
243. Tanoue A. New topics in vasopressin receptors and approach to novel drugs: effects of vasopressin receptor on regulations of hormone secretion and metabolisms of glucose, fat, and protein. J Pharmacol Sci 2009; 109: 50-52.
244. 1a receptors in regulation of arterial pressure during acute and chronic osmotic stress. Am J Physiol Regul Integr Comp Physiol 2011; 300: R460-R469.
245. Yang Z, Han D, Coote JH. Cardiac sympatho-exicatory action of PVN-spinal oxitocin neurones. Auton Neurosci 2009; 147: 80-85.
246. Yao Y, Fu LY, Zhang X, van den Pol AN. Vasopressin and oxytocin excite MCH neurons, but not other lateral hypothalamic GABA neurons. Am J Physiol Regul Integr Comp Physiol 2012 [Epub ahead of print] PMID:22262306.